BioCentury
ARTICLE | Clinical News

ISV-403: Phase I

February 17, 2003 8:00 AM UTC

ISV filed an IND to start Phase I trials of ISV-403 in the second quarter of 2003. As a result of the filing, ISV will receive an equity investment from BOL, which has exclusive rights to ISV-403 worl...